title: Treating venous thromboembolism in patients with cancer.
abstract: Venous thromboembolism (VTE) is a major cause of morbidity and mortality among patients with cancer. Although much is known about the factors that contribute to VTE risk, pre-emptive therapy in high-risk populations is clearly indicated in only a few clinical situations. Low-molecular-weight heparin is still the recommended class of anticoagulants for cancer-associated VTE. Management of VTE in patients with renal failure, hemorrhagic brain metastases, thrombocytopenia and coagulopathy remains challenging with few safe and effective alternatives. Novel oral agents are currently being investigated and may play a role in the future in the treatment of cancer-associated VTE.
authors.affiliation: Jane Anne Nohl Division of Hematology, Department Medicine, University of Southern California-Keck School of Medicine, Los Angeles, CA 90033, USA.
authors.forename: Caroline
authors.initials: C
authors.lastname: Piatek
authors.forename: Casey L
authors.initials: CL
authors.lastname: O'Connell
authors.forename: Howard A
authors.initials: HA
authors.lastname: Liebman
mesh_terms: D000925:Anticoagulants / Q000627:therapeutic use; D001932:Brain Neoplasms / Q000556:secondary; D006470:Hemorrhage / Q000150:complications; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use; D006801:Humans; D009369:Neoplasms / Q000150:complications / Q000473:pathology*; D011655:Pulmonary Embolism / Q000150:complications; D051437:Renal Insufficiency / Q000150:complications; D012307:Risk Factors; D054556:Venous Thromboembolism / Q000150:complications / Q000628:therapy*
chemical_list: D000925:Anticoagulants; D006495:Heparin, Low-Molecular-Weight